MiMedx beats Q4 sales estimates; announces $100 mln share buyback

MiMedx

25/02/2026 21:19

Overview

Wound care firm's Q4 net sales grew 27% yr/yr, beating analyst expectations

Adjusted EBITDA for Q4 beat analyst expectations

Company announced $100 mln share repurchase program

Outlook

MiMedx estimates 2026 net sales between $340 mln and $360 mln

Company expects 2026 adjusted EBITDA margin in mid-to-high teens

Medicare reimbursement changes may impact 2026 revenue

Result Drivers

WOUND AND SURGICAL GROWTH - Co reported strong double-digit growth in Wound and Surgical sales, driven by new product introductions

PRODUCT MIX - Favorable product mix contributed to increased gross margins

Company press release: ID:nGNX5dWcKc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$118.10 mln
$106.78 mln (6 Analysts)
Q4 Net Income
$15.19 mln
Q4 Adjusted EBITDA
Beat
$29.38 mln
$25.93 mln (4 Analysts)
Q4 Gross Profit
$99.04 mln
Q4 Operating Income
$21.08 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MiMedx Group Inc is $10.00, about 86.9% above its February 24 closing price of $5.35

The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)